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Menthol’s potential effects on nicotine dependence:
a tobacco industry perspective
Valerie B Yerger
ABSTRACT
Objective To examine what the tobacco industry knows
about the potential effects menthol may have on nicotine
dependence.
Methods A snowball strategy was used to
systematically search the Legacy Tobacco Documents
Library (http://legacy.library.ucsf.edu/) between 22
February and 29 April, 2010. Of the approximately 11
million documents available in the Legacy Tobacco
Documents Library, the iterative searches returned tens
of thousands of results. We qualitatively analysed a final
collection of 309 documents relevant the effects of
menthol on nicotine dependence.
Results The tobacco industry knows that menthol
overrides the harsh taste of tobacco and alleviates
nicotine’s irritating effects, synergistically interacts with
nicotine, stimulates the trigeminal nerve to elicit a ‘liking’
response for a tobacco product, and makes low tar, low
nicotine tobacco products more acceptable to smokers
than non-mentholated low delivery products.
Conclusion Menthol is not only used in cigarettes as
a flavour additive; tobacco companies know that menthol
also has sensory effects and interacts with nicotine to
produce tobacco products that are easier to smoke,
thereby making it easier to expose smokers, especially
those who are new and uninitiated, to the addictive
power of nicotine.
INTRODUCTION
The isomer l-menthol, which has been used as an
additive in cigarettes since 1926,1 is extracted from
the peppermint plant, Mentha arvensis.2 The
concentration of menthol in cigarettes varies
according to the product and the flavour or effect
desired,3 but is present in 90% of all tobacco
products, both ‘mentholated’ and ‘non-mentho-
lated’.4 Menthol added to cigarettes at appropriate
levels imparts a minty flavour and sensory effects
on the smoker.5 6 The market share of filter-tipped
identifiably mentholated products increased from
1.1% in 1956 to 20% in 2006.7
Menthol cigarettes are overwhelmingly popular
among African American smokers (83% compared
with 24% of US white smokers),8 owing to, at least
in part, tobacco companies’ disproportionately
promoting their menthol brands in African Amer-
ican communities.9e13 It may not yet be clear what
are the relative risks of smoking menthol ciga-
rettes;14 15 however, African Americans, who
smoke fewer cigarettes per day16 and generally have
a later onset of smoking initiation compared to
white people,17 have higher rates of lung cancer and
other tobacco-related diseases.18 19 Cotinine,
a biomarker of nicotine exposure,20e22 is higher in
African American smokers than in white smokers,23
suggesting African Americans metabolise nicotine
more slowly,23 24 which could be because they
smoke mentholated cigarettes.25e27
The issue of menthol goes beyond the African
American population. Analysing data from the
2003 and 2006e7 Tobacco Use Supplement to the
Current Population Surveys, Lawrence et al noted
some other racial/ethnic groups were also more
likely than white smokers to consume mentholated
cigarettes.28 Menthol cigarettes have been specifi-
cally designed to attract youths,29 30 whose use of
mentholated cigarettes has increased from 2000 to
2008.8 31 Tobacco companies also targeted their
menthol marketing campaigns at women,9 32 who
use mentholated cigarettes at much higher rates
than their male counterparts.17 Additionally,
mentholated cigarettes are actively promoted in
other parts of the world and make up a substantial
proportion of the market in many developing
countries.4 33
Several studies published in the open literature
suggest there is a relation between menthol and
nicotine dependence. Fagan et al demonstrated that
despite smoking fewer cigarettes per day, menthol
smokers showed greater signs of nicotine depen-
dence as evidenced by being more likely to smoke
their first cigarette within 5 minutes of waking.34
The time to first cigarette is a more robust indicator
of dependence than the number of cigarettes
smoked in a day or the Fagerström test of nicotine
dependence (FTND).35 36 Other public health
researchers have also shown that menthol smokers
have a significantly shorter time to the first ciga-
rette of the day than non-menthol smokers.37e39
Muscat et al, however, did not find a significant
association between smoking mentholated ciga-
rettes and FTND scores39 and Hyland et al did not
find an association between the use of mentholated
cigarettes and quitting, the amount smoked, or the
time to first cigarette upon waking.40
Menthol’s sensory and respiratory effects
may lead to greater nicotine dependence in
adult smokers5 6 41e44 and in adolescents who
smoke.30 31 38 45 Smoking mentholated cigarettes
produces a cooling sensation in the upper airway,46
which is innervated by trigeminal somatosensory
neurons.47 Menthol activates the cold sensitive ion
channel TRPM8,48 which is the underlying mech-
anism for the trigeminal detection of menthol in
the head and neck regions such as the nasal and oral
cavities.49 Menthol’s cooling action depresses
respiratory activity, resulting in breath holding,
which then leads to increased lung exposure to
nicotine.5 42 The addictive properties of nicotine
have been clearly demonstrated.50 51 It has been
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suggested by public health researchers that menthol potentiates
nicotine dependence by making the “poisons [eg, addictive
nicotine] go down easier”.52
Evidence from internal tobacco company documents leads to
a similar conclusion: tobacco companies not only knew menthol
has sensory effects and interacts with nicotine, but that they
used this knowledge to produce tobacco products that would
be easier to smoke. Including menthol in cigarettes makes it
easier to expose smokers, especially those who are new and
uninitiated, to the addictive power of nicotine.
METHODS
As described in detail elsewhere,53 we used a snowball sampling
design54 to search the Legacy Tobacco Documents Library
(LTDL) (http://legacy.library.ucsf.edu/) between 22 February
2010 and 29 April 2010. We combined traditional qualitative
methods55 with iterative search strategies tailored for the LTDL
dataset.56 Initial keyword searches combined terms related to:
menthol, nicotine, dependence and addiction; and brand names
such as Kool, Newport and Salem. This initial set of keywords
resulted in development of further search terms and combina-
tions of keywords (eg, ‘menthol pharmaco*’, ‘menthol/nicotine
interaction’, and ‘nicotine delivery’). For each set of results, the
first 100e200 documents were reviewed to locate documents
relevant to the research questions. A final collection of 309
documents was analysed for this paper, of which 50 were
deemed representative and cited.
RESULTS
Menthol is not just a flavour additive
In a 1982 RJ Reynolds interoffice memo written in anticipation
of questions from consumers concerned about menthol, RJ
Reynolds biochemist Charles Nystrom told Tim Cahill of the
company ’s public relations department that menthol has been
‘used as a flavour additive in cigarettes’ since 1926 and that
‘there is no evidence that menthol has any effect on the smoker
other than the effect of menthol on the taste and flavour of the
cigarette’.1 Cahill subsequently responded to consumer letters
inquiring about the effects of menthol in cigarettes, assuring
consumers that menthol was used as a flavour additive and had
no other effect or addictive properties.57
Sensory properties of menthol
Three years earlier, in 1979, the Roper Organization conducted
a study of 1367 menthol and non-menthol smokers for Philip
Morris, which concluded that the addition of menthol to ciga-
rettes masked the harshness of tobacco, which makes cigarettes
more desirable to some smokers.58
The Roper report concluded that menthol smokers are
attracted to menthol’s drug-like properties: ‘cooling effects;
clean, antiseptic effects; slightly numbing, anaesthetic effects;
and heady, lifting effects’.58 Menthol’s cooling effect appears to
be a result of chemical action that occurs at or near nerve
endings which are associated with the sensation of cold.59 These
nerve endings are located in the nasal, oral and skin membranes.
When menthol is added to cigarettes and smoked, this cooling
sensation is also experienced in the lungs. The cooling sensation
is dose sensitive. Increasing the amount of menthol beyond
a certain limit would not generally result in a greater degree of
cooling, but would cause an increase in other sensations such as
tingling, stinging and burning.60
Because of its sensory properties, menthol is able to mask the
harshness of tobacco.61 In 1982, the Creative Research Group
(CRG) conducted for British American Tobacco discussion
groups with menthol smokers or ‘potential users’ aged
18e50 years on consumer perceptions of mentholated cigarettes.
CRG concluded in its report ‘Project Crawford’ that mentho-
lated cigarettes “undeniably impart a cooling influence, and .
a by-product of this is to reduce harshness and to modify or
mask the tobacco taste”.61 Supporting this notion that menthol
is more than a flavour additive, CRG concluded that the flavour
of menthol was not a ‘significant reward’ and that menthol
smokers build tolerance to the taste of menthol but continue to
get menthol’s sensory effects.61
Regarding menthol’s ability to mask tobacco taste, CRG
concluded:
There is no question that menthol has a significant masking effect
on both the taste of the tobacco and the harshness of the smoking
experience. Some menthol smokers seek as much masking effect as
possible, attempting to eradicate the tobacco taste altogether.
.
[Mentholation] can still function in its masking role and yet can
have lost a large portion of its own [flavour].61
The report included quotes from some of the discussion group
participants that reveal the part menthol plays in covering up
tobacco taste. For example, one participant said, “As far as I am
concerned, I want the menthol to completely cover up the taste of the
tobacco. I don’t like the taste of tobacco”. Another participant
reported, “If the menthol was gone, I wouldn’t be able to stand the
cigarette!” [Emphasis in original.]61
In addition to making cigarettes smoother and less harsh,
menthol’s cooling effect alleviates nicotine’s irritating effect.
The tobacco companies were well aware that younger, inexpe-
rienced smokers had low tolerance for irritation and tobacco
taste.62 63 RJ Reynolds conducted studies in 1983 on nicotine
and menthol to better understand the “independent and joint
effects of nicotine and menthol on smoker perception”.64 One of
its studies concluded, “Nicotine [is].a major irritant in cigarette
smoke while menthol is known to produce a cooling effect and
is often used to alleviate sensations of irritation”.64 In contrast
to what RJ Reynolds was telling its customers in 1982,57 a 1976
confidential RJ Reynolds research report written by chemist Dr
Mary Evelyn Stowe to Dr Donald H Piehl, manager of the
company ’s Chemical Research Division, indicates that RJ
Reynolds had known for more than three decades that menthol,
even at subliminal levels too low to be detected by smokers,
reduced ‘that nasal sting, tongue bite, and harshness’ of
tobacco.65
Tobacco industry research on menthol and nicotine
As consumers were becoming increasingly more concerned
about the harmfulness and addictiveness of nicotine, Philip
Morris, for example, sought to design denicotinised cigarettes
and menthol played a crucial part in the company ’s research.66
During the late 1980s, Philip Morris scientists conducted in-
house testing of various prototypes of ART, an “alkaloid [nico-
tine] reduced tobacco” product.67 68 ARTcigarettes had 0.12 mg
nicotine/cigarette, compared to 0.20 mg or more of nicotine per
cigarette in conventional cigarettes. One ART prototype, the
ART-extracted, was completely denicotinised. Owing to the
absence or decreased nicotine delivery, non-mentholated ART
prototypes lacked ‘impact’. Impact, perceived by the smoker as
a ‘kick’ or ‘grab’ in the back of the mouth and throat when
inhaling a cigarette,6 69 is crucial in providing much of the
immediate satisfaction gained from smoking.70 Phillip Morris
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found the mentholated prototypes of ART to be ‘subjectively
superior ’ to the non-mentholated versions because they were
the only ART prototypes that provided any impact.71 When
further testing the mentholated ART prototypes, Philip Morris
scientists found menthol provided this perceived impact because
it produced some nicotine-like effects.68
Menthol and nicotine interaction
In 1989, Philip Morris scientists discovered that ‘menthol and
nicotine interact in a very interesting fashion’.72
Specifically, perceived impact seems to vary as a function of the
delivery levels of menthol and/or nicotine in smoke.it seems that
menthol level almost exclusively determines degree of impact. In low
nicotine delivery cigarettes, it appears that nicotine and menthol
combine in an additive manner to determine degree of impact [emphasis
added].72
Philip Morris continued its research on menthol cigarettes by
combining menthol with varying levels of nicotine.73 74 Philip
Morris found in a factorial study that combined four levels of
menthol (0.00 mg, 0.41 mg, 0.85 mg and 1.95 mg per cigarette)
and three levels of nicotine (0.08 mg, 0.41 mg and 0.91 mg per
cigarette) that the addition of menthol either increased or
decreased impact, depending on whether, and to what degree,
nicotine was present.75 The study concluded that cigarettes
without nicotine were preferred more when menthol was added.
Those cigarettes that had low or intermediate levels of menthol
were preferred over those cigarettes with the highest menthol
level.
Between 1989 and 1991, Philip Morris scientists conducted
smoking panel tests as part of product development to deter-
mine specific combinations of menthol and nicotine needed in
low nicotine delivery cigarettes to attain a desired impact.76e79
In 1990, Philip Morris scientists conducted electrophysiological
studies to record and measure objective information about the
effects of nicotine on the central nervous system (CNS).68 75 80
Smokers were attached by electrodes to a machine that recorded
brain activity impulses.81 These pattern-reversal evoked poten-
tial measurements were ‘very sensitive to nicotine delivery in
a dose-related manner ’.68 While conducting these studies,
menthol’s electrophysiological effects on the CNS became
apparent. In a memo they distributed to other company
researchers, Philip Morris research scientists Frank Gullotta,
C S Hayes and B R Martin concluded, “as we had seen before,
adding menthol to the [nicotine] extracted model had the effect
of increasing impact. More interestingly, and something we had
not seen before however, menthol had the effect of low[er]ing
impact in those cigarettes containing nicotine”.68
In 1990, Philip Morris conducted a study on menthol-nicotine
interactions. Varying the amount of menthol and nicotine
delivery affected impact scores.82 Test cigarettes with the
highest level of menthol but the lowest level of nicotine delivery
had the highest impact score (figure 1).82 As the nicotine level
decreases while the menthol level increases, impact increases
(figure 2).79
What became apparent to Philip Morris scientists from these
studies in the late 1980s and early 1990s is that impact increased
when nicotine per puff was low and menthol per puff was
high.79 82 Therefore, in 1991, Philip Morris took into account the
levels of all three variablesdtar, nicotine and mentholdwhen
predicting and manipulating the impact of low nicotine delivery
cigarettes.83 An abstract of Gullotta’s work, which he faxed in
1995 to Philip Morris’ research scientist Gerry Nixon,84
concluded, “menthol increased ‘impact’ for the low nicotine
delivery cigarettes. The effect of menthol was most
pronounced for the cigarette with the lowest nicotine delivery.
It was concluded that menthol has a pronounced effect on
nicotine-derived ‘impact’. Therefore, menthol levels must be
considered when targeting cigarettes for degree of perceived
impact”.85
In 1985, RJ Reynolds conducted product development studies
of full flavour and low tar cigarette prototypes among full
flavour menthol smokers. RJ Reynolds produced a report
(lacking the names of any authors or contributors) containing
the findings from these studies.86 These qualitative studies
indicated that higher overall acceptance among full flavour
menthol smokers was associated with high nicotine flavour,
regardless of menthol delivery. The report also concluded, “At
Figure 1 Philip Morris test cigarettes with the highest level of menthol
but the lowest level of nicotine delivery had the highest impact scores.82
Figure 2 As nicotine levels decrease and menthol levels increase,
impact score increases.79
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moderately high tobacco nicotine levels (w2.00%), almost any
pack menthol.approximates the mean ideal strength. However,
at lower tobacco nicotines (w1.45%ew1.83%), pack menthols
must increase (from 0.34% to 0.62%), in conjunction with
tobacco nicotines, to maintain mean ideal strength”.86 Menthol
was also shown to ease the flow of smoke through the filter.86
Menthol’s role in cigarettes containing low levels of nicotine
and tar
In order to achieve substantial reductions in nicotine and tar
yields, tobacco companies developed and used a number of
manufacturing and design techniques,87 which included ‘highly
efficient filters, perforations of the filter tipping paper, adjusted
porosities and burn characteristics of the cigarette rod wrapping
paper, and the use of expanded tobacco’.88 In 1972, Philip Morris
considered how a reduction in tar level would affect a cigarette’s
nicotine/tar ratio and if such a change in the ratio would affect
that cigarette’s acceptability and marketability.
The nicotine/tar ratio of all cigarettes.is .0760.01. We have no
acceptability data for nicotine/tar ratios outside this range. Since
the trend in tar delivery is downward, and since nicotine is
presumed to be that which is sought by the smoker, does a cigarette
with a high nicotine/tar ratio have market potential?89
Lorillard Tobacco Company was also aware of the increasing
market demand for cigarettes that would deliver lower levels of
tar. In 1975, Lorillard received a report of the Marketing Corp of
America’s marketing study that discussed the market demand
for and a ‘strong likelihood of continued growth’ of low tar/
nicotine brands.90
Though the industry may have been aware that there was the
likelihood that low tar/nicotine cigarettes would be attractive to
a growing number of smokers concerned about effects of ciga-
rettes on their health, some of the findings from the 1979 Roper
study conducted for Philip Morris in 1979 revealed low tar
cigarettes were tasteless, failed to satisfy the smoker and were
harder to smoke.
The appeal of low tars is simple and singledbetter for you, less
harmful, easier on the lungs, throat, etc. The weakness or objection
to low tars is also simpledtasteless, lacking in satisfaction. But
since lack of taste is the #1 drawback to low tars, the question
occurs as to whether it is possible to “spray” or “inject” extra taste
into low tars.
.
[L]ow and ultra low tar menthol smokers are better satisfied by
their cigarettes than their non-menthol counterparts.menthol
makes up in some way for the light or “pale” qualities of a low tar
cigarette.58
Tobacco companies discovered they could manipulate the level
of tar and nicotine in their cigarettes, and with the help of
menthol, design ‘light’, ‘mild’ and ‘ultra light’ cigarettes that
would be acceptable to consumers.91 According to the 1979
Roper report, for example, menthol compensated for the reduced
taste in ‘light cigarettes’, which otherwise would have been less
satisfying to smokers.58 In 1982, Philip Morris conducted a focus
group study with menthol smokers of various menthol brands.
The study revealed:
People want to know they are smoking a cigarette, not just sucking
air.Many of the smokers describe the non-menthol low delivery
cigarette as lacking taste, papery, or like burning leaves.Most of
the smokers believed menthol cigarettes are smoother and less
harsh than non-menthol.92
Consistent with what other tobacco companies reported,
Brown and Williamson (B&W) recognised the role menthol
played in making mild, light and ultra light cigarettes more
attractive to smokers than non-mentholated counterparts.
According to an undated product development report, when
B&W increased filtration and ventilation to decrease the amount
of tar delivered to the smoker, it increased the amount of
menthol to maintain the appeal of low tar cigarettes (table 1).91
An undated document indicates that British American
Tobacco also recognised the need for an optimal balance between
menthol and nicotine:
Another aspect to consider is the balance between the menthol and
the nicotine in the smoke. This should not be a problem in lower
delivery products as the combined effects, remembering menthol
produces a physiological effect ‘menthol impact’, would not be
unacceptably high. Problems can arise if there is a high level of
either or both. The theory is that the two components stimulate
the same receptors and compete with one another.93
Menthol’s sensory stimulation
Menthol affects the response of many receptors to stimulation.
Physiological effects of menthol are dose sensitive.60 Small
concentrations of menthol are more effective than large quan-
tities, which will depress receptor stimulation. After prolonged,
chronic exposure, response to receptor stimulation is also
depressed. By 1990, Philip Morris understood menthol was
a complex compound and that liking mentholated cigarettes
was complex. Philip Morris scientists produced a 199-page
research and development report on their chemical senses
research, which encompassed ‘the development of a funda-
mental understanding of those physical/chemical and biological
system interactions that result in a favourable subjective
response to the product’.73
Philip Morris scientists were, however, limited in their ability
to measure these feeling factors and realised that product
development would require a more focused research programme
on chemical senses. Menthol was an integral part of this plan.
The 1993 operational plans for its Sensory Technology Program
revealed that Philip Morris scientistsdrepresented by scientific
affairs director Richard Carchman in an internal
memodintended to utilise their knowledge of the ‘synergistic
interaction’ between menthol and nicotine to develop a product
that was low tar yet had superior sensory characteristics.94
Philip Morris’ strategic plan for 1993e1997 described the
development of molecular models to identify the processes that
lead to human sensory perceptions, including the mechanisms
by which nicotine and menthol bind to receptor sites to elicit
sensory effects.87 Philip Morris was specifically interested in
understanding these mechanisms to improve the ‘sensory effi-
cacy ’ of both nicotine and menthol in order to increase the
company ’s menthol market share.87
Mechanism underlying menthol’s sensory effects
The trigeminal nerve is the fifth cranial nerve and is widely
distributed throughout the head. Trigeminal chemoreception
Table 1 The transfer efficiency rate of menthol
decreases with increasing filtration and ventilation91
Tar range % Transfer efficiency % Menthol applied
Full flavour 15e16 0.35e0.45
Milds 12e13 0.45e0.55
Lights 8e10 0.60e0.80
Ultras 1e5 0.80e1.25
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was of interest to the tobacco industry because nicotine stim-
ulated this nerve,95 and the trigeminal is essential to eliciting
a ‘liking’ response for a tobacco product.73 According to 1988
Philip Morris interoffice correspondence, the impact provided by
menthol is probably mediated by the nociceptive fibres of at
least two nerves: glossopharyngeal and trigeminal.71
In 1989, Philip Morris established its ‘Trigeminal Panel’,
composed of smoking employees in the company ’s research and
development department,68 to conduct research ‘to screen for
compounds [including menthol] which might possess nicotine-
like sensory characteristics’.96 The panel identified compounds
which elicited trigeminal responses and exhibited nicotine-like
sensory characteristics.97 The panellists were assessed for their
electrophysiological and subjective effects on the CNS.98e101
Menthol produced some nicotine-like CNS and subjective effects
in humans71 97 and was found to be a ‘partial replacement’ for
nicotine.78
RJ Reynolds also conducted in-house research on menthol and
demonstrated menthol elicited taste and smell responses by
stimulating the trigeminal cold fibres, the gustatory (taste) and
olfactory (smell) nerves and nociceptors (sensory receptors that
respond to pain).60 These combined actions provide what RJ
Reynolds called the ‘total menthol response’ in an undated
document.60
Menthol and nicotine metabolism
It is unclear if tobacco companies conducted research on
menthol’s effects on nicotine metabolism. An undated B&W
study on nicotine and cotinine intentionally excluded menthol
smokers from the sample,102 as did a report on a plasma cotinine
study done for RJ Reynolds.103 Although in 1985 B&W
considered doing comparative blood cotinine testing on menthol
and non-menthol smokers,104 subsequent searching in the LTDL
did not reveal evidence that this research was done. Such
research, if rigorously designed, could provide understanding of
menthol’s role, if any, in nicotine metabolism. Industry scien-
tists reviewed scientific articles published in the open literature,
including research showing menthol may increase toxic expo-
sure by inhibiting nicotine metabolism and detoxification of
tobacco-specific lung carcinogens.15
Tobacco companies understood menthol to be metabolised
primarily in the liver, via its conjugationwith glucuronic acid, and
subsequent excretion in the urine as glucuronide.105 The amount
excreted varies, depending on the dose of menthol and the specific
animal.105 A study on the metabolism of l-menthol in rats by
organic chemists in India found in the Philip Morris collection
reported that there was “[m]aximal induction of cytochrome
P-450 and its reductase.upon 3 days of repeated treatment with
l-menthol”.106 Although the study was done on rats, it had
relevance for humans becausedin most smokersdnicotine is
eventuallymetabolised to cotinine via a pathway that is catalysed
by hepatic cytochrome P4502A6 (CYP2A6).107 108
According to a published non-industry study on menthol
glucuronidation in humans,109 cited in a 1986 privileged and
confidential attorneys’ work product report on menthol that
was created by the industry law firm Covington & Burling,105
human subjects given 500 g of l-menthol rapidly but incom-
pletely metabolised it into menthol glucuronide. In all, 77.5% of
the 10e20 mg of menthol administered orally to the human
subjects was recovered in the urine in 11 hours, with no addi-
tional menthol recovered in the subsequent 25 hours. The
authors of the study concluded that not all of the menthol
appears to be conjugated, and ‘the metabolic fate of the menthol
that is not conjugated is unknown’.105 Conjugation with
glucuronic acid (glucuronidation) serves as an essential mecha-
nism for eliminating numerous drugs and chemicals, including
menthol, in humans and other animals.110 111 A 2001 report
prepared by Philip Morris’ product integrity team on the use of
menthol as an ingredient in cigarettes presents evidence that
Philip Morris continued to cite published studies that concluded
menthol had no effect on nicotine metabolism.112 There was no
indication that Philip Morris conducted its own in-house studies
of menthol and nicotine absorption.
DISCUSSION
In 1982, RJ Reynolds was telling consumers there was no
evidence menthol had any ‘effect on the smoker other than the
effect of menthol on the taste and flavour of the cigarette’,1
a position the tobacco industry still maintained in 2010. At the
15 July 2010 FDA Tobacco Products Scientific Advisory
Committee (TPSAC) meeting in Bethesda, Maryland, Jane Y
Lewis, senior vice president for Altria Client Services, on behalf
of Philip Morris (PM) USA, publicly stated “menthol is a flavor
[and that] PM USA only adds menthol to the flavor recipes of
cigarettes labeled as menthol cigarettes”.2
The companies’ internal documents tell a different story.
Tobacco companies have known at least since the early 1980s
that the flavour of menthol is not a ‘significant reward’ for
menthol smokers.61 Rather, menthol’s ability to provide an
‘extra something’ beyond its flavour to smokers58 has been of
interest to tobacco companies. The evidence presented in this
paper shows menthol is not just an ingredient added in
a proprietary recipe to make cigarettes taste a certain way, as
suggested in the 15 July 2010 public presentations by the
tobacco industry to the FDA TPSAC.2 113
William R True, senior vice president of Lorillard Tobacco
Company ’s Research and Development, also publicly stated on
15 July 2010 at the FDA TPSAC meeting that his company uses
‘menthol at very low levels’ in non-menthol brands.113 Our
research of the internal tobacco documents supports True’s
statement. As a cooling or anaesthetic agent, menthol, even at
low or subliminal levels, masks the harshness of tobacco and
alleviates the irritation associated with nicotine.61 64 65 Adding
menthol to cigarettes makes them easier to smoke, which is
a strategy to attract young and inexperienced smokers.30 62 63
Tobacco companies’ in-house studies on menthol showed that
menthol has some nicotine-like sensory effects. Stimulating
sensory receptors can strengthen the conditioned aspects of
smoking.50 Tobacco companies explored a number of ways to
manipulate levels of menthol and took advantage of menthol’s
physiological effects on the trigeminal cold fibres, the gustatory
and olfactory nerves, and nociceptors to make the smoking
experience more pleasurable for some smokers.
Prompted by consumer concerns of the harmfulness of ciga-
rettes, tobacco companies sought to design cigarettes with lower
delivery levels of nicotine and tar. Tobacco companies experi-
mented with varying ratios of tar, nicotine and menthol in
product prototypes and discovered menthol synergistically
interacted with nicotine. Subsequent in-house research showed
nicotine levels could be reduced in cigarettes and with the
appropriate level of menthol added, low nicotine delivery ciga-
rettes could be produced that would be appealing to
consumers.64 114 Menthol’s role in the design of low nicotine
delivery cigarettes became apparent in the 1980s, when tobacco
companies determined the amount of menthol needed to attain
a desired impact at any given nicotine level. By increasing the
amount of menthol up to a certain threshold level, tobacco
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companies designed cigarettes with lower nicotine content
without sacrificing impact. The use of menthol, especially in
low nicotine delivery cigarettes, provides the strength and
impact that higher nicotine level cigarettes deliver. These find-
ings suggest adjusting menthol levels compensates for the
reduced appeal of non-mentholated low nicotine cigarettes.
Industry documents retrieved for this study did not reveal the
companies conducted their own studies on how menthol
affected dependence measures such as FTND or the biomarkers
of tobacco smoke exposure such as cotinine, carbon monoxide
(CO), carboxyhaemoglobin or thiocyanate.115 However, a search
of the open scientific literature identified two industry studies
on menthol and smoke exposure biomarkers. One study
compared 112 menthol and non-menthol smokers and found no
difference in the level of biomarkers between moderately heavy
menthol and non-menthol cigarette smokers.116 The second one,
a cross-sectional, observational study in 3341 adult cigarette
smokers, also reported not finding any differences in the level of
smoke exposure biomarkers between menthol and non-menthol
smokers.117 Also identified in the literature search were
numerous articles written by industry research scientists on the
effects of non-mentholated smoking on the biomarkers of
exposure.118e128 Since none of these industry-funded studies
included menthol as a variable, there were missed opportunities
to contribute to the understanding of menthol’s role in nicotine
dependence, nicotine metabolism, nicotine exposure or cigarette
consumption. However, studies published by peer-reviewed
public health researchers have increased the knowledge base of
how menthol affects biomarkers of exposure. Several of these
public health studies show that menthol smokers, when
compared with non-menthol smokers, have higher carbon
monoxide levels,27 129e133 which correlates highly with nicotine
exposure.134
Tobacco companies did not appear to conduct in-house
studies on menthol to assess how menthol may affect depen-
dence or exposure measures. Instead, tobacco companies,
concerned about how to increase their share of the cigarette
market, focused on testing new products and manipulating the
menthol and nicotine levels in cigarettes. Internal industry
research indicates that menthol has some nicotine-like effects,
interacts directly with nicotine to produce cigarettes that are
easier to smoke and makes low nicotine delivery products more
acceptable to consumers. The cooling and local anaesthetic
effects of menthol make mentholated cigarettes easier to smoke
than non-mentholated cigarettes. Menthol, therefore, facilitates
smoking and contributes to smoking initiation among inexpe-
rienced and uninitiated smokers.29 Because of its effects on
smokers, who thus are exposed to the addictive power of
nicotine, menthol contributes to the overall burden of tobacco-
related disease. Banning the use of menthol in all cigarettes will
lead to fewer people starting to smoke29 and more people
quitting,135 which will have a positive impact on the public
health.
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